Showing 101-110 of 220 results for "".
Histiocytoses: A Review of the Most Recent Classification System
https://practicaldermatology.com/topics/skin-cancer-photoprotection/histiocytoses-a-review-of-the-most-recent-classification-system/20503/A look at the proposed new classification system, grouping the histiocytoses into five categories, with tabular summaries for differential diagnosis.Currents
https://practicaldermatology.com/topics/practice-management/currents/21098/Bugs in DermatologyPhysician Spotlight: Andrew C. Krakowski, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-andrew-c-krakowski-md/20842/Moisturizers for Skin Diseases: New Insights
https://practicaldermatology.com/topics/atopic-dermatitis/moisturizers-for-skin-diseases-new-insights/22977/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-37/23755/GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal reUpdates on Nitric Oxide As a Topical Anti-infective
https://practicaldermatology.com/topics/practice-management/updates-on-nitric-oxide-as-a-topical-anti-infective/21071/NO continues to show promise as a safe and effective topical treatment candidate for acne and other infectious dermatoses.Updating Approaches to Psoriasis
https://practicaldermatology.com/topics/psoriasis/evaluating-the-state-of-psoriasis-care/21660/Recent guidelines from the National Psoriasis Foundation point to new directions in research and therapy that will continue to shape psoriasis therapy.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.AI and Skin of Color: Hidden Biases Raise Questions
https://practicaldermatology.com/topics/skin-of-color/ai-and-skin-of-color-hidden-biases-raise-questions/23994/AI holds potential for practitioners, but it’s important to think critically about what data we use to build models.